The 2026 Taiwan headache society guideline on the use of treatments targeting the CGRP pathway

The introduction of CGRP-targeted therapy has markedly influenced migraine care in Taiwan, together with accumulating evidence and clinical experience. Therefore, the Treatment Guideline Subcommittee of the Taiwan Headache Society updated its 2022 consensus on preventive migraine therapy, with a specific focus on CGRP-targeted therapies. This updated guideline also provides evidence-based recommendations and practical guidance on the use of gepants following their introduction in Taiwan. After reviewing recent clinical trials, meta-analyses, and international guidelines, and integrating expert panel opinions, we developed this new guideline to update the treatment options, recommended populations, timing of initiation and discontinuation, and practical considerations for CGRP-targeted therapy, organised into ten clinical questions. According to the current consensus, preventive treatment is recommended for patients with ≥4 headache days per month, significant disability, failure of or contraindications to acute therapy, complicated migraine with severe aura (such as hemiplegic migraine or migrainous infarction), or when patient preference favours prevention after balancing potential benefits and risks. Currently, CGRP-targeted therapies for migraine prevention include anti-CGRP monoclonal antibodies, namely erenumab, fremanezumab, galcanezumab, and eptinezumab, as well as small-molecule CGRP receptor antagonists, including rimegepant and atogepant. In this 2026 updated guideline, CGRP-targeted therapy is listed as one of the first-line treatment options for both episodic and chronic migraine prevention. A history of failure of multiple preventive medications is not required before initiating CGRP-targeted therapy, as early initiation may provide better migraine control than delayed treatment. For both episodic and chronic migraine, the Taiwan Headache Society recommends that CGRP-targeted therapy may be continued for up to 12 months. This update is crucial for improving migraine care and highlights the importance of continuous CGRP-targeted therapy, rather than premature or unnecessary treatment interruption.

Authors

Institutions

Publication Details

Journal
Journal of the Chinese Medical Association
Published
2026-11-13
DOI
https://doi.org/10.1097/jcma.0000000000001446
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The 2026 Taiwan headache society guideline on the use of treatments targeting the CGRP pathway

Jong‐Ling Fuh, Tu‐Hsueh Yeh, Tzu-Chou Huang, Chi Ieong Lau et al.
2 links
Journal of the Chinese Medical Association
Migraine and Headache Studies
article

The 2026 Taiwan headache society guideline on the use of treatments targeting the CGRP pathway

Jong‐Ling Fuh, Tu‐Hsueh Yeh, Tzu-Chou Huang, Chi Ieong Lau, Yi-Chia Liaw, Ching-Sen Shih, Jen-Feng Liang, Jr‐Wei Wu, Shih‐Pin Chen, Tsung-Wei Hou, Yung‐Chu Hsu, Yi‐Hsien Tu, Chun Ming Yang, Tzu‐Hsien Lai, Chun-Pai Yang, Wei-Ta Chen, Ping-Kun Chen, Fu-Chi Yang, Yen-Yu Chen, Kang-Hsu Lin, Yen-Feng Wang, Shuu-Jiun Wang, Kao-Chang Lin, Wei-Hung Chen
article en

Abstract

The introduction of CGRP-targeted therapy has markedly influenced migraine care in Taiwan, together with accumulating evidence and clinical experience. Therefore, the Treatment Guideline Subcommittee of the Taiwan Headache Society updated its 2022 consensus on preventive migraine therapy, with a specific focus on CGRP-targeted therapies. This updated guideline also provides evidence-based recommendations and practical guidance on the use of gepants following their introduction in Taiwan. After reviewing recent clinical trials, meta-analyses, and international guidelines, and integrating expert panel opinions, we developed this new guideline to update the treatment options, recommended populations, timing of initiation and discontinuation, and practical considerations for CGRP-targeted therapy, organised into ten clinical questions. According to the current consensus, preventive treatment is recommended for patients with ≥4 headache days per month, significant disability, failure of or contraindications to acute therapy, complicated migraine with severe aura (such as hemiplegic migraine or migrainous infarction), or when patient preference favours prevention after balancing potential benefits and risks. Currently, CGRP-targeted therapies for migraine prevention include anti-CGRP monoclonal antibodies, namely erenumab, fremanezumab, galcanezumab, and eptinezumab, as well as small-molecule CGRP receptor antagonists, including rimegepant and atogepant. In this 2026 updated guideline, CGRP-targeted therapy is listed as one of the first-line treatment options for both episodic and chronic migraine prevention. A history of failure of multiple preventive medications is not required before initiating CGRP-targeted therapy, as early initiation may provide better migraine control than delayed treatment. For both episodic and chronic migraine, the Taiwan Headache Society recommends that CGRP-targeted therapy may be continued for up to 12 months. This update is crucial for improving migraine care and highlights the importance of continuous CGRP-targeted therapy, rather than premature or unnecessary treatment interruption.

Journal of the Chinese Medical Association
Fu Jen Catholic University (TW), Asia Eastern University of Science and Technology (TW), Tri-Service General Hospital (TW), National Yang Ming Chiao Tung University (TW), National Chung Hsing University (TW), China Medical University (TW), Taipei Medical University Hospital (TW), Taipei Veterans General Hospital (TW), Kuang Tien General Hospital (TW), Taichung Veterans General Hospital (TW), An-Nan Hospital (TW), Far Eastern Memorial Hospital (TW), China Medical University Hospital (TW), Chi Mei Medical Center (TW), Kaohsiung Veterans General Hospital (TW), Shin Kong WHS Memorial Hospital (TW), Changhua Christian Hospital (TW), University College London (GB), Taipei Medical University (TW), National Defense Medical Center (TW)
Good health and well-being
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon